ERBB2 and cancer: Trastuzumab conjugated nanoparticles showed uptake specificity to HER2-positive cancer cells over HER2-negative cells after a short contact time of 30 minutes to 2 hours [37], while nanoparticles without trastuzumab (more positively charged) entered the cells in a non-specific manner after long exposure.